pharmaphorum5d
EU clears Enhertu for HER2-low breast cancer
The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu ... options in the late-line setting," commented Ken Keller, Daiichi Sankyo's head of oncology.
Seeking Alpha14d
Daiichi Sankyo Company, Limited (DSKYF) Q3 2024 Earnings Call Transcript
We will now would like to start Daiichi Sankyo's Financial Results ... CEO, Manabe; Oncology Business Unit Head, Ken Keller; and Oncology business heads for the US and Europe will be on stage ...
Pharm Exec25d
FDA Approves AstraZeneca, Daiichi Sankyo’s Datroway for Previously Untreated Unresectable, Metastatic HR-Positive, HER2-Negative Breast Cancer
Datroway is the latest addition to our portfolio of innovative cancer treatments and marks the fourth medicine from our oncology pipeline to receive approval in the US,” said Ken Keller, global head, ...
Pharm Exec17d
FDA Approves AstraZeneca, Daiichi Sankyo’s Enhertu for Unresectable or Metastatic Hormone Receptor-Positive, HER2-Low Breast Cancer
The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan ... another paradigm shift in how certain breast cancers can be treated,” said Ken Keller, global head, oncology ...